Skip to main content
Premium Trial:

Request an Annual Quote

NCI Approves Affymetrix's Terms for GeneChip Sales

Premium

BETHESDA, Md.--Affymetrix, the Santa Clara, Calif., maker of the GeneChip probe array technology, said the US National Cancer Institute has agreed to terms and conditions set forth by Affymetrix that will make the technology accessible to academic and not-for-profit researchers in a manner consistent with the institute's guidelines. Researchers will be able to publish scientific results via traditional and emerging electronic means, collaborate with academic, government, and commercial scientific colleagues, and retain rights to their genetic discoveries. Affymetrix said it will negotiate volume price discounts with each institution separately.

The cancer institute said its concerns about the broad availability of high-throughput molecular analysis technologies to the cancer and general biomedical research community led to its negotiations with Affymetrix. The institute said it will provide administrative supplements to its grantees to purchase DNA equipment, as well as to special programs in research excellence that it supports, in order that comprehensive molecular technologies may be applied to translational cancer research.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.